75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - CONDENSED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Funding Arrangements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Collaboration, License and Other Agreements link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Equity Incentive Plan and Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Equity Incentive Plan and Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Fair Value Measurements - Summary of Financial Assets Fair Value Measurement on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Funding Arrangements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Collaboration, License and Other Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Equity - Shares of Common Stock Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Equity Incentive Plan and Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Equity Incentive Plan and Stock-Based Compensation - Summary of Total Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Equity Incentive Plan and Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Equity Incentive Plan and Stock-Based Compensation - Summary of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculation (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Net Loss Per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Segment Reporting - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Segment Reporting - Summary of Disaggregated Amounts that Comprise Research and Development Expenses (Details) link:presentationLink link:calculationLink link:definitionLink Weighted-Average Grant Date Fair Value, Vested and released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted average exercise price, Forfeited/expired MGC Venture Partners QP 2018, LP [Member] MGC venture partners QP 2018, LP. MGC Venture Partners QP 2018, LP Entity Incorporation, State or Country Code Preferred Stock, Shares Issued Preferred stock, shares issued Statement of Financial Position Location, Balance [Domain] Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable, Total Accounts payable Plan Name [Axis] Equity [Abstract] Entity Current Reporting Status Rights agreement description. Rights Agreement Description Rights agreement, description US Government Agencies Debt Securities [Member] U.S. Government Agency Securities Consulting and Outside Services Consulting and outside services. Consulting and outside services Operating expenses: Operating Expenses [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Commitments and Contingencies [TextBlock] Commitments and Contingencies Common stock, shares authorized Common Stock, Shares Authorized Share-Based Payment Arrangement, Tranche Three [Member] Over 48 months of Service Option repricing reduced exercise price of each eligible option Option Repricing Reduced, Exercise Price of Each Eligible Option Option repricing reduced, exercise price of each eligible option. Investments Investment, Policy [Policy Text Block] Number of option period for funding from government contract Number of Option Period for Funding From Government Contract Number of option period for funding from government contract. Document Fiscal Period Focus Accounting Standards Update 2023-09 [Member] ASU 2023-09 Entity Shell Company Other Other Accrued Liabilities, Current Short-term investments Short-Term Investments [Member] Segments Segment Reporting, Policy [Policy Text Block] Cash and cash equivalents Cash equivalents Cash and Cash Equivalent Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Common stock, shares issued and sold Common stock, shares issued Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Asset Class [Domain] Statement [Table] Aggregate maximum payments upon achievement of development milestones Aggregate maximum payments upon achievement of development milestones. Weighted average grant-date fair value, options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Employees purchase price of common stock as percentage of lower of fair market value Statement [Line Items] Entity Filer Category Total liabilities and stockholders' equity Liabilities and Equity Weighted Average Exercise Price per Share, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets NIAID Contract National Institute of Allergy and Infectious Diseases [Member] National Institute of Allergy and Infectious Diseases Stock issued, price per share Original issue price Offering price, per share Stock Options Authorized For Future Issuance Investment Income, Interest Interest income Long-term investments Debt Securities, Available-for-Sale, Noncurrent Asset-Backed Securities [Member] Asset-backed Securities Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] Restructuring Charges External Research and Development Expenses [Abstract] External research and development expenses. External research and development expenses: Percentage of maximum commissions to be paid to agent of gross proceeds of sale. Percentage Of Maximum Commissions To Be Paid To Agent Of Gross Proceeds Of Sale Percentage of maximum commissions to be paid to agent of gross proceeds of sale Related Party [Member] Related Party Significant Accounting Policies [Text Block] Basis of Presentation and Summary of Significant Accounting Policies Vesting [Domain] Number of stock option previously granted Total Options outstanding, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Placement agent fees and other offering costs Placement Agent Fees and Other Offering Costs Placement agent fees and other offering costs. Schedule of computation of basic and diluted net loss per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Anacor licensing agreement. Anacor Licensing Agreement [Member] Anacor Licensing Agreement Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share attributable to common stockholders, basic Options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Total Options outstanding, Beginning balance Total Options outstanding, Ending balance Warrants Warrants Policy [Policy Text Block] Warrants. Grant funding in advance amount. Grant Funding In Advance Amount Grant funding in advance amount Liabilities, Current Total current liabilities Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Brii biosciences agreement. Brii Biosciences Agreement [Member] Brii Biosciences Agreement Newly Hired Employees. Newly Hired Employees [Member] Newly Hired Employees Government contract fund increased amount Government Contract Funding Increased Amount Government contract funding increased amount. Accounting Standards Update [Axis] Equity, Attributable to Parent [Abstract] Stockholders' equity: Entity Small Business Accrued liabilities Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Liabilities, Total Option repricing description Share-Based Compensation Arrangement by Share-Based Payment Award, Plan Modification, Description and Terms Accumulated deficit Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Proceeds from government contract Proceeds from Government Contract Proceeds from government contract. Proceeds from eligible funding under government contract Series A Series A redeemable convertible preferred stock. Series A Redeemable Convertible Preferred Stock [Member] Series A Redeemable Convertible Preferred Stock University of georgia research foundation. University of Georgia Research Foundation [Member] UGARF Grant Equity Incentive Plan and Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amendment Flag 2022 Equity Incentive Plan Two Thousand Twenty Two Equity Incentive Plan [Member] Two thousand twenty two equity incentive plan. Proceeds from Sale, Maturity and Collection of Investments Proceeds from Sale, Maturity and Collection of Investments, Total Maturities of investments Class of Warrant or Right, Number of Securities Called by Warrants or Rights Issuance of warrants to purchase common stock Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Entity Address, Postal Zip Code Cash flows used in operating activities Cash flows used in operating activities Cash flows used in operating activities Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Exchange of Common Stock for Prefunded Warrants, Shares Exchange of common stock for prefunded warrants, shares Exchange of common stock for pre-funded warrants, shares Pre-funded warrants exchange, Shares Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Common Stock Common Stock Weighted average exercise price, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Interest Receivable, Current Accrued interest receivable Aggregate development and regulatory milestones eligible to receive Aggregate development and regulatory milestones eligible to receive. Entity Address, Address Line One Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Fair Value Hierarchy and NAV [Axis] Earnings Per Share [Abstract] Income Tax, Policy [Policy Text Block] One Big Beautiful Bill Act Funding Arrangements Funding Arrangements [Text Block] Funding arrangements text block. Statement of Financial Position Location, Balance [Axis] OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Unrealized (loss) gain on investments Transfer of level 2 to level 1 Fair Value Asset Level 2 To Level 1 Transfer Amount Fair value asset level 2 To level 1 transfer amount. Document Type Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Entity Central Index Key Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net increase (decrease) in cash and cash equivalents Subsequent Event Type [Domain] Anti-dilutive securities excluded from computation of diluted per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Balance Sheet Related Disclosures [Abstract] Common stock, par value Common Stock, Par or Stated Value Per Share Accounting Standards Update [Domain] Net proceeds from issuance of pre-funded warrants Proceeds from Issuance of Warrants After Completion of 12 months of Service Share-Based Payment Arrangement, Tranche One [Member] Weighted Average Remaining Contractual Life, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Debt securities, available-for-sale investments Estimated Fair Value Debt Securities, Available-for-Sale Debt Securities, Available-for-sale, Total External Research and Development Expenses External research and development expenses. Total external research and development expenses Total Options outstanding, Exercised Total Options Outstanding, Exercised Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of stock options, shares Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Payment of non-refundable upfront payment. Payment Of Non Refundable Upfront Payment Payment of non-refundable upfront payment Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of noncash financing items Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Option issued and outstanding. Option Issued And Outstanding [Member] Option Issued and Outstanding Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Current Fiscal Year End Date Adjuvant global health agreement. Adjuvant Global Health Agreement [Member] Adjuvant Global Health Agreement Document Quarterly Report Exchange of Common Stock for Warrants Settled, Shares Exchange of common stock for warrants settled, shares. Exchange of common stock for warrants settled, shares Dr. Rob Readnour [Member] Dr. Rob Readnour. Dr. Rob Readnour Entity Address, State or Province Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares issued Beginning Balance Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Comprehensive loss Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Grant income recognized. Grant Income Recognized Grant income recognized Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Common stock reserved for future issuance (in shares) Shares of common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Government Contract Funding Reduced Amount Government contract funding reduced amount. Government contract funding reduced amount Underwritten offering. Underwritten Offering [Member] Underwritten Offering Incentive Stock Option Incentive stock option. Summary of Total Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Long-term investments Long Term Investments [Member] Long term investments. Number of years, sales royalty required to be paid Number of Years Sales Royalty Required to Be Paid Number of years sales royalty required to be paid. Subsequent Event [Member] Subsequent Event Short-term investments Debt Securities, Available-for-Sale, Current Debt Securities, Available-for-sale, Current, Total Antidilutive Securities [Axis] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Percentage of annual increase in shares reserved for future issuance on common stock outstanding. Percentage of annual increase in shares reserved for future issuance on common stock outstanding. Proceeds from Sale of Debt Securities, Available-for-Sale Available-for-sale, sale of investments Accrued professional services expenses Accrued Professional Services Expenses Accrued professional services expenses Accumulated Other Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Dr. Rob Readnour One [Member] Dr. Rob Readnour One. Dr. Rob Readnour One Preferred Stock, Value, Issued Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Issued Financial Instrument [Axis] Current assets: Assets, Current [Abstract] Upfront payment received. Upfront Payment Received Upfront payment received Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Preferred stock dividend for each share of common stock Number of days convenience upon written notice until first regulatory approval. Number Of Days Convenience Upon Written Notice Until First Regulatory Approval Number of days convenience upon written notice until first regulatory approval. Segment Reporting [Abstract] Exchange of Common Stock for Warrants, Shares Exchange of common stock for warrants shares. Exchange of common stock for warrants, shares Summary of Financial Assets Fair Value Measurement on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Current liabilities: Liabilities, Current [Abstract] Related Party Transactions [Abstract] Ending balances, shares Shares, Outstanding Beginning balances, shares Beneficial ownership limitation maximum percentage to be increased upon 61 days prior written notice Beneficial ownership limitation maximum percentage to be increased upon 61 days prior written notice Proceeds from Stock Plans Proceeds from issuance of common stock under the ESPP Commitments and Contingencies Commitments and contingencies (Note 7) Weighted Average Grant Date Fair Value, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Beginning Balance General and Administrative Expense General and Administrative Expense [Member] Net Loss Net Loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Proceeds From Grant Funding Proceeds from grant funding. Amount received in grant funding Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average number of shares used in computing net loss per share, basic Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders, basic Collaboration, License And Other Agreements [Abstract] Collaboration, license and other agreements. Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Increase (Decrease) in Other Current Liabilities Other current liabilities Share-Based Payment Arrangement, Plan Modification, Incremental Cost Option repricing resulted incremental stock compensation expense for vested and unvested options Appreciation Rights Or Performance Awards [Member] Appreciation rights or performance awards. Appreciation Rights Or Performance Awards Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Proceeds from Issuance of Private Placement Gross proceeds from private placement Royalty percentage. Royalty Percentage Royalty percentage Research and development related expenses related party. Research and Development Related Expenses Related Party Research and development related expense related party Related Party Transactions Related Party Transactions Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Ending balances Equity, Attributable to Parent Total stockholders' equity Beginning balances Payments to Acquire Investments Payments to Acquire Investments, Total Purchases of investments Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Existing employees. Existing Employees [Member] Existing Employees Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Statement of Stockholders' Equity [Abstract] Share-Based Payment Arrangement, Tranche Two [Member] Over 36 months of Service Stock options issued and outstanding. Stock Options Issued And Outstanding [Member] Stock Options Issued And Outstanding Clinical Trials Expenses Clinical trials expenses. Clinical trials expenses Use of Estimates Use of Estimates, Policy [Policy Text Block] Entity Address, Address Line Two Collaboration, License And Other Agreements [Line Items] Collaboration, license and other agreements. Accrued research and development-related expenses current. Accrued Research And Development Related Expenses Current Accrued research and development-related expenses Schedule of Accrued Liabilities [Table Text Block] Summary of Accrued Liabilities Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Plan Name [Domain] Non Rule10B51 Arr Modified Flag Non-Rule10B5-1 Arr Modified Flag. Non-Rule 10b5-1 Arrangement Modified Recent Accounting Pronouncements Not Yet Adopted Recent Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block] Recent accounting pronouncements not yet adopted policy. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Class of Warrant or Right, Outstanding Warrants outstanding Related and Nonrelated Parties [Axis] Government Assistance [Table] Other Directors or Officers [Member] Other directors or officers. Accounting Standards Update [Extensible Enumeration] Entity Address, City or Town Long term purchase commitment period Long-Term Purchase Commitment, Period Number of Reportable Segments Number of reportable segment Security Exchange Name Schedule of Redeemable Convertible Preferred Stock Temporary Equity [Table Text Block] Net unrealized gain (loss) on available-for-sale investments Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total Net unrealized gain (loss) on available-for-sale investments Counterparty Name [Axis] Rule10b51Arr Modified Flag Rule10b51Arr Modified Flag. Rule 10b5-1 Arrangement Modified Other External Research and Development Other external research and development. Other external research and development Antidilutive Securities, Name [Domain] Cash and cash equivalents at the end of the period Cash and cash equivalents at the beginning of the period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Statistical Measurement [Domain] Bill and melinda gates foundation. Bill and Melinda Gates Foundation [Member] BMGF BMGF Grant Class of Warrant or Right, Exercise Price of Warrants or Rights Nominal exercise price Exercise price Total current assets Assets, Current Share-based payment arrangement expense Total stock-based compensation Share-Based Payment Arrangement, Expense Document Period End Date Title and Position [Axis] Fair Value Hierarchy and NAV [Domain] Total Options Outstanding, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Statement of Financial Position [Abstract] Restricted Stock Units (RSUs) [Member] RSU Unvested RSUs Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Gates Foundation [Member] Gates foundation. Gates Foundation Grant Vesting [Axis] Collaboration, License And Other Agreements [Table] Collaboration, license and other agreements. Class of Stock [Axis] Warrants and Rights Outstanding, Maturity Date Dividend expiration date Grant Agreements. Grant Agreements, Policy [Policy Text Block] Grant Agreements Liabilities Total liabilities Government Award Government award Maximum amount eligible to receive under cost-reimbursement contract award Eric Easom [Member] Eric Easom. Eric Easom Financial Instruments [Domain] Earnings Per Share, Diluted, Other Disclosure [Abstract] Government Award Cumulative Contract Funding Amount After Reduction Government award cumulative contract funding amount after reduction. Maximum amount eligible to receive under cost-reimbursement cumulative contract award after reduction MGC Venture Partners 2018, LP [Member] MGC venture partners 2018, LP. MGC Venture Partners 2018, LP Government Assistance, Type [Axis] Debt securities unrealized loss position, more than12 months number of positions Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average number of shares used in computing net loss per share, diluted Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders, diluted Securities Act File Number Entity File Number Unrealized gain (loss) on available-for-sale investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Cover [Abstract] RSA Restricted Stock Award (RSA). Restricted Stock Award (RSA) [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] U.S. Treasury Securities US Treasury Securities [Member] Maximum number of shares of common stock that may be issued Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of Operating Segments Number of operating segment Sale of Stock [Domain] Segment Reporting Disclosure [Text Block] Segment Reporting General and administrative General and Administrative Expense General and Administrative Expense, Total Proceeds From Issuance Of Pre-funded Warrants Net Of Issuance Costs Proceeds from issuance of pre-funded warrants net of issuance costs. Proceeds from issuance of pre-funded warrants in the 2026 Private Placement, net of placement agent fees and other offering costs Total Options Outstanding, Forfeited/expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Two Thousand Twenty Four Bill and Melinda Gates Foundation [Member] 2024 Bill and Melinda Gates Foundation. 2024 BMGF Grant Purchase price Class of Warrant or Right, purchase price Per share Class of Warrant or Right, purchase price Per share. Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized stock-based compensation expense Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Assumed dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments Common stock, shares outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Document Transition Report Operating Expenses Total operating expenses Accrued Liabilities, Current [Abstract] Research and Development Expense Research and development Total research and development expenses Risks and Uncertainties Risks and Uncertainties Policy Policy Text Block Risks and Uncertainties Policy Policy Text Block Statement of Cash Flows [Abstract] Stock Issued During Period, Value, New Issues Issuance of common stock in the 2026 Private Placement, net of placement agent fees and other offering costs Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Fair value asset level 1 to level 2 transfer amount. Transfer of level 1 to level 2 Fair Value Asset Level 1 To Level 2 Transfer Amount Unaudited Interim Condensed Financial Information Unaudited Interim Condensed Financial Information [Policy Text Block] Unaudited interim condensed financial information. Equity Redeemable Convertible Preferred Stock Equity [Text Block] Earnings Per Share [Text Block] Net Loss Per Share Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Summary of RSU Activity Cash cash equivalents and investments. Cash Cash Equivalents And Investments Cash, cash equivalents and investments Offering Cost Included In Accounts Payable And Accrued Liabilities Offering cost included in accounts payable and accrued liabilities. 2026 Private Placement Offering costs included in accounts payable and accrued liabilities Net loss Net loss Net loss Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Government Assistance [Line Items] Accrued offering costs current. Accrued Offering Costs Current Accrued offering costs Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Assets Assets [Abstract] Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other assets Funding of option extends estimated completion of contract term Funding of Option Extends Estimated Completion of Contract Term Funding of option extends estimated completion of contract term. Document Fiscal Year Focus Government Award Decreased Amount Government award decreased amount. Award reduction amount Cash flows from investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Accounts payable Accounts Payable, Current Accounts Payable, Current, Total Number of option exercised for government contract Number of Option Exercised for Government Contract Number of option exercised for government contract. 2017 Equity Incentive Plan Two Thousand Seventeen Equity Incentive Plan [Member] Two thousand seventeen equity incentive plan. Research and Development Expense Research and Development Expense [Member] Aggregate maximum payments upon achievement of commercial and sales threshold milestones Aggregate maximum payments upon achievement of commercial and sales threshold milestones. Government Contractors, Policy [Policy Text Block] Government Contract Accounting Standards Update 2020-06 [Member] ASU 2020-06 Proceeds from Stock Options Exercised Proceeds from exercise of stock options Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] Aggregate gross sales Sale of Stock, Consideration Received on Transaction Number of common stock value sold Net loss attributable to common stockholders Net loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Share-Based Payment Arrangement [Abstract] Sale of Stock [Axis] University Georgia Research Foundation [Member] University Georgia Research Foundation [Member] UGARF Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided by investing activities Private Placement [Member] Private Placement 2026 Private Placement Title of 12(b) Security Money Market Funds [Member] Money Market Funds Related and Nonrelated Parties [Domain] Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss Allowance for credit losses Share-based compensation arrangement by share-based payment award, increase in number of shares. Share-Based Compensation Arrangement by Share-Based Payment Award, Increase in Number of Shares Increase in number of annual shares Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Other Liabilities, Noncurrent Other non-current liabilities Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Weighted average exercise price, Ending balance Weighted average exercise price, Beginning balance Weighted average exercise price per share, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Additional Paid-in Capital Additional Paid-In Capital Measurement Frequency [Domain] Government Contract Receivable Government contract receivable Statement of Income Location, Balance [Axis] Change in Accounting Principle, Accounting Standards Update, Adoption Date Underwriting agreement. Underwriting Agreement [Member] Underwriting Agreement Trading Symbol Government contract income recognized Government Contract Income Recognized Government contract income recognized. Related Party Transaction [Table] Subsequent Event Type [Axis] Accrued compensation Employee-related Liabilities, Current Employee-related Liabilities, Current, Total Cash flows from financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Fair Value Measurements Recurring Fair Value, Recurring [Member] Entity Ex Transition Period Beneficial ownership limitation minimum percentage of outstanding common stock Beneficial ownership limitation minimum percentage of outstanding common stock. Increase Decrease in Accrued Compensation Increase decrease in accrued compensation. Accrued compensation Issuance of Pre-funded Warrants In The 2026 Private Placement, Net of Placement Agent Fees Issuance of pre-funded warrants in the 2026 private placement, net of placement agent fees. Issuance of pre-funded warrants in the 2026 Private Placement, net of placement agent fees and other offering costs Share based compensation arrangement by share based payment award increase percentage of common stock outstanding. Share Based Compensation Arrangement By Share Based Payment Award Increase Percentage Of Common Stock Outstanding Percentage of common stock outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Maximum percentage in payroll deductions to purchase shares of common stock Grant award amount. Grant Award Amount Grant award amount Personnel Related Expenses Personnel related expenses. Personnel related expenses Equity Components [Axis] Equity Component [Domain] Asset Class [Axis] Investments Investments Investments, Total Incentive Stock Option or Restricted Stock Unit. Incentive Stock Option or Restricted Stock Unit [Member] Incentive Stock Option or RSU Issuance of common stock upon release of restricted stock units, shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Initial Public Offering IPO [Member] Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under the ESPP, shares Private placement closing date Private Placement Closing Date Private placement closing date. Award contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period CommonStockVotingRights Common Stock, Voting Rights Schedule of Shares of Common Stock Reserved for Future Issuance Schedule of common stock shares reserved for future issuance. Schedule Of Common Stock Shares Reserved For Future Issuance Maximum Statistical Measurement [Axis] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price, Exercised Common Stock, Value, Issued Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 35,985,599 and 27,413,171 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively Accrued clinical trial-related expenses Accrued Clinical Trial Related Expenses Current Accrued Clinical Trial Related Expenses Current Exchange Agreements Exchange Agreements [Member] Exchange agreements. Preferred Stock, Shares Authorized Preferred stock, shares authorized Related Party Transaction [Line Items] Sales Agreement. Sales Agreement [Member] Sales Agreement ESPP, Authorized for Future Issuance Employee Stock [Member] Government committed contract funding amount Government Committed Contract Funding Amount Government committed contract funding amount. Entity Registrant Name Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Reactive Biosciences Agreement [Member] Reactive biosciences agreement. Reactive Biosciences Agreement Additional paid-in capital Additional Paid in Capital Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Total Government Assistance, Type [Domain] Measurement Frequency [Axis] Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Proceeds from issuance of common stock under the ESPP Other Comprehensive Income (Loss), Tax [Abstract] Other comprehensive loss: Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Funding Arrangements [Abstract] Funding arrangements. Entity Common Stock, Shares Outstanding Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive (loss) gain Rights agreement. Rights Agreement [Member] Rights Agreement Accounting policies. Accounting Policies [Line Items] Accounting Policies [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Issued Total assets Assets Weighted Average Remaining Contractual Life, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Income Statement [Abstract] Number of available options under government contract Number of Available Options under Government Contract Number of available options under government contract. Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Common stock, shares sold Common stock issued and sold Sale of Stock, Number of Shares Issued in Transaction Stock Issued During Period, Shares, New Issues Stock issued during period, shares Issuance of common stock in the 2026 Private Placement, net of placement agent fees and other offering costs, shares Two Thousand Twenty Two Employee Stock Purchase Plan [Member] Two Thousand Twenty Two Employee Stock Purchase Plan [Member] 2022 Employee Stock Purchase Plan Vested and released Vested and released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share attributable to common stockholders, diluted Summary of Disaggregated Amounts that Comprise Research and Development Expenses Schedule of Segment Reporting Information, by Segment [Table Text Block] Title and Position [Domain] City Area Code Gilbert Lynn Marks [Member] Gilbert Lynn Marks. Gilbert Lynn Marks Counterparty Name [Domain] Number of days convenience upon written notice thereafter. Number Of Days Convenience Upon Written Notice Thereafter Number of days convenience upon written notice thereafter Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under the ESPP Aggregate gross proceeds of common stock and pre funded warrants Aggregate gross proceeds of common stock and pre funded warrants. Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Loss from operations Loss from operations Loss from operations Operating Income (Loss) Accumulated Deficit Retained Earnings [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Noncash Expense, Total Non-Statutory Stock Options Non Statutory Stock Options [Member] Non statutory stock options. Level 1 Fair Value, Inputs, Level 1 [Member] Impairment losses of investments. Impairment losses related to investments Impairment Losses Of Investments Class of Stock [Line Items] Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Change in Accounting Principle, Accounting Standards Update, Adopted [true false] JOBS Act Accounting Election Jobs Act Accounting Election Policy [Policy Text Block] Jobs act accounting election policy. Two Thousand and Twenty Six Sales Agreement [Member] Two thousand and twenty six sales agreement. 2026 Sales Agreement Schedule of potentially dilutive securities that were not included in the diluted per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Corporate Debt Securities [Member] Corporate Debt Securities Entity Interactive Data Current Unvested Restricted Stock Units. Unvested Restricted Stock Units Unvested Restricted Stock Units [Member] Statement of Income Location, Balance [Domain] Cash flows used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Net accretion of discount on investments Accretion (Amortization) of Discounts and Premiums, Investments Pre-Funded Warrants [Member] Pre-funded warrants. Pre-funded Warrants Entity Tax Identification Number Local Phone Number Other Liabilities, Current Other current liabilities Other liabilities current Unrecognized share-based compensation expense related to unvested share options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Pre Funded Warrants [Member] Pre-funded warrants. Pre-funded Warrants Accounting Policies [Abstract] Internal Research and Development Expenses [Abstract] Internal research and development expenses. Internal research and development expenses: Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Proceeds From Issuance of Common Stock in Private Placement Net of Issuance Costs Proceeds from issuance of common stock in private placement net of issuance costs Proceeds from issuance of common stock in the 2026 Private Placement, net of placement agent fees and other offering costs Cash and Cash Equivalents [Member] Cash and cash Equivalents Class of Stock [Domain] Accounting policies. Accounting Policies [Table] Accounting Policies [Table] Commercial Paper [Member] Commercial Paper Shares of common stock remained available for future issuance Options available for grant, Ending balance Options available for grant, Beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized share-based compensation expense expects to recognize over a weighted-average period Contract term Contract Term Contract term. Stock, Class of Stock [Table] Entity Emerging Growth Company Collaboration, License and Other Agreements Collaboration, License And Other Agreements [Text Block] Collaboration, license and other agreements. At-the-market offering. At The Market Offering [Member] At the Market Offering